Guestbook Form: Will the requirement by the US FDA to simultaneously co-develop companion diagnostics (CDx) delay the approval of receptor tyrosine kinase inhibitors for RTK-rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) non-small cell lung cancer globally?

By using this website and any of the materials made available through it, you agree to abide by the Terms of Use of ScholarBank@NUS and any additional terms of use attached to this item. These materials can be used for academic research, learning and teaching purposes only for yourself. Under no circumstances should the materials be disseminated to another person or used for commercial purposes.
I have carefully read and fully understood the Terms of Use and agree to accept the same.
Cancel